Aprea Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| APRE | RKV.V | PCSA | ALLR | TPST | ACRV | |
|---|---|---|---|---|---|---|
| Market cap | 6.36M | 4.27M | 5.41M | 17.18M | 9.26M | 74.56M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.3 | — | -0.5 | -1.3 | -0.4 | -1.1 |
| Price/book | 0.3 | -2.0 | -17.0 | 4.9 | -6.8 | 0.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −60.75% | −5.41% | −77.18% | −7.38% | −95.29% | −17.73% |
| Today | −1.90% | 0.00% | −0.26% | −4.42% | −1.13% | +4.19% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All APRE news ›Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
DOYLESTOWN, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for…
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
A wee1 kinase inhibitor is a drug that blocks the Wee1 enzyme, a cellular “brake” that slows cell division to allow DNA repair. By releasing that brake, the inhibitor forces rapidly dividing, damaged cells—like many cancer cells—into…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.financialcontent.com2
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.